Devyser secures SEK 8.9M five-year tender and strengthens Italian position
Devyser secures SEK 8.9M five-year tender and strengthens Italian position
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in Regione Basilicata, Italy, with a total value of SEK 8.9 million. The tender includes several of Devyser's key diagnostic products and is expected to significantly increase annual revenues, while further strengthening the company's position in Italy, one of its most important European markets.
"We are pleased to have been awarded this tender and to continue supporting genetic diagnostics in Italy," said Jan Wahlström, CEO of Devyser. "The inclusion of products addressing important clinical areas such as CFTR-related disorders, thalassemia, and male infertility highlights the strength of our portfolio and our commitment to improving patient care through high-quality genetic testing."
The tender is valid for a period of five years and covers several of Devyser's key diagnostic products that aid in the detection of CFTR-related disorders, thalassemia, chromosomal aneuploidy and male infertility. These products support healthcare providers with accurate and reliable genetic testing, enabling informed clinical decision-making and improved patient outcomes.
The tender win reflects the continued confidence placed in Devyser's genetic testing solutions and provides greater long-term visibility through the five-year contract period. It also marks another important milestone in Devyser's strategy to expand access to advanced genetic diagnostics across Europe through long-term partnerships with laboratories and healthcare providers.